Skip to content

Jazz succeeds in 2 late-stage sleep apnea studies

March 20, 2017

Jazz Pharmaceuticals (JAZZ +6.1%) perks up on increased volume in response to its announcement of positive results from two Phase 3 trials assessing Orphan Drug-tagged JZP-110, a selective dopamine and norepinephrine reuptake inhibitor, for the treatment of excessive sleepiness in adults with obstructive sleep apnea (OSA).

Both studies, TONES 3 and TONES 4, met their co-primary endpoints.

Results from TONES 2, assessing JZP-110 for the treatment of excessive sleepiness associated with narcolepsy, should be available next quarter. An NDA is on tap for Q4.

http://bit.ly/2ne1vxP

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: